Clinical trials: Tumor Microenvironment
Prostate Cancer
Investigation of Tumor Microenvironment After CRPC Along With Before and After Neoadjuvant Therapy for Prostate Cancer
In recent years, the clinical research of immunotherapy including PD-1 antibody and CD3 bispecific antibody in prostate cancer has been increasing day by day.
- Trial name
- NCT05522907
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Vitamin D Deficiency
Nutrition and Body Composition in Acute Lymphoblastic Leukemia
Many adolescents with acute lymphoblastic leukemia (ALL) have been found to have low bone density by the end of treatment. This can lead to long-term suffering in survivors due to poor bone health.
- Trial name
- NCT01317940
- Testing
- Vitamin D and Calcium Citrate
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Los Angeles
Prostate Cancer
Heterogeneity of Tertiary Lymphoid Structures Predicts Distinct Malignancy and Immune Microenvironment in Prostate Cancer: a Retrospective Cohort Study
The aim of this study was to reveal the predictive value of spatial heterogeneity and maturity difference of tertiary lymphoid structure in pathological sections of prostate cancer patients for clinical features and prognosis.
- Trial name
- NCT06484127
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Fudan University
Sequence Analysis
Analysis of Tumor Mutations and Tumor Microenvironment Using Archival Paraffin-embedded Tumor Specimens
Genomic alterations have long been recognized as an important factor in tumor formation and drive tumor cell growth. However, the degree of genomic mutation (tumor mutation load, TMB) varies widely between tumors.
- Trial name
- NCT03719222
- Testing
- non intervention
- Where
- Taiwan
- Volunteers
- 600 people
- Sponsor
- ACT Genomics
Immune Microenvironment, Luminal A
Tumor Immune Mechanism of Axillary Lymph Node Metastasis in Early Luminal Type A Breast Cancer
Luminal type A breast cancer is a type with good clinical prognosis, and the proportion of lymph node metastasis is low, but a small number of patients have more lymph node metastasis when the primary tumor is very small, and the…
- Conditions
- Immune Microenvironment, Luminal A, Lymph Node Metastases
- Trial name
- NCT04322331
- Testing
- no intervention
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Peking University People's Hospital
Pediatric Solid Tumors
Dissecting Tumour MicroenvirOnment in Solid Paediatric Tumour to Improve Adoptive Cell Therapy
Pediatric solid tumors exhibit a low mutational burden, limited availability of neoantigens, and poor infiltration of tumor-infiltrating lymphocytes (TILs) within the tumor microenvironment (TME), characteristics that reduce the…
- Trial name
- MOST (NCT07240207)
- Where
- Italy
- Volunteers
- 44 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Acute Lymphoid Leukemia, Acute Myeloid Leukemia in Children
Study of the Medullary Microenvironment in Acute Childhood Leukemia
Acute leukemia (AL) is the most common cancer in children. Despite the optimization of chemotherapy treatments and the development of supportive care, a certain number of LAs relapse and/or progress to death of the child.
- Trial name
- MILA (NCT05792007)
- Testing
- Biological sampling in patients, Biological sampling in control patients
- Where
- 3 sites in France
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University Hospital, Tours
Muscle-Invasive Bladder Carcinoma, Urothelial Carcinoma (UC)
Immune-Stromal Landscape in Muscle-Invasive Bladder Cancer
Bladder cancer is a significant global health issue. When the cancer spreads into the muscle layer of the bladder (muscle-invasive bladder cancer), a common treatment is the surgical removal of the bladder (radical cystectomy).
- Conditions
- Muscle-Invasive Bladder Carcinoma, Urothelial Carcinoma (UC), Bladder Cancer, Muscle-Invasive Urothelial Bladder Carcinoma
- Trial name
- NCT07525349
- Volunteers
- 100 people
- Sponsor
- Assiut University
Lung Cancer, NSCLC
Modulatory Effect of Prodigiosin or Pioglitazone on TIME and the Crosstalk to Immune-Checkpoint Protein(s)
Lung cancer is one of the most common and serious types of cancer. Lung tumor cells exploit immune checkpoint proteins (ICPs) to maintain immune tolerance and thus promote tumor progression and invasion.
- Trial name
- NCT06502249
- Where
- Egypt
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Epithelial High Grade Serous Ovarian Cancer
Elements of Adaptive Immunity in Epithelial Ovarian Cancer
The study seeks to evaluate the presence and correlation with clinical outcome of several components of adaptive immunity (TILs, TLS, plasma cells and PD-L1 expression) in tumor specimens of patients with EOC treated with…
- Trial name
- NCT07528911
- Testing
- Assessment of elements of adaptive immunity in tumor biopsies
- Where
- Greece
- Volunteers
- 687 people
- Sponsor
- Hellenic Cooperative Oncology Group
Cancer of Head and Neck
Targeting Potassium Channels to Reprogram Glioblastoma Microenvironment: in Vitro and in Vivo Studies
The investigators want to verify the hypothesis that targeting the calcium-activated (KCa3.1) and the voltage-dependent K channel (Kv1.3) could be a valuable therapeutic strategy to reprogram cells of the innate immune system…
- Trial name
- NCT03954691
- Testing
- brain tumor-immune cells communication
- Where
- 2 sites in Italy
- Volunteers
- 50 people
- Sponsor
- Neuromed IRCCS
PSMA Positive Tumors or Tumor Tissues
PSMA-specific CAR-T Cell Therapy
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of PSMA-specific CAR-T cell therapy in patients with PSMA positive tumor.
- Trial name
- NCT04429451
- Testing
- 4SCAR-PSMA T cells
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Colon Adenocarcinoma
Role of Immunoscore® in Stage II-III Colorectal Cancer
The proposed study is a bidirectional analytical study, composed of a retrospective and a prospective cohorts. Patients with stage II - III colorectal cancer undergoing oncological surgery will be analyzed.
- Trial name
- NCT05422547
- Testing
- Immunoscore Colon Test
- Where
- 2 sites in Brazil
- Volunteers
- 100 people
- Sponsor
- D'Or Institute for Research and Education
Gallbladder Cancer
Artificial Intelligence-based Tumor Microenvironment Analysis for Prognosis Prediction in Gallbladder Cancer
This retrospective study aims to investigate the prognostic significance of artificial intelligence (AI)-powered analysis of tumor-infiltrating lymphocytes (TILs) and the tumor microenvironment (TME) in patients with resected…
- Trial name
- NCT07092397
- Where
- South Korea
- Volunteers
- 266 people
- Sponsor
- Samsung Medical Center
Melanoma
A Storage Facility for Tissues Obtained From Patients With Malignant Melanoma
This study collects and stores blood and tumor samples from patients with malignant melanoma and healthy individuals. The purpose of this study is to gain a better understanding of the causes of melanoma and how melanoma tumors…
- Trial name
- NCT04567706
- Testing
- Biospecimen Collection
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
Pancreatic Adenocarcinoma Metastatic, Ovarian Serous Adenocarcinoma
To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovarian and Colorectal Cancers
Pancreatic, ovarian and colorectal cancers are difficult to treat using chemotherapy and immune therapies.Currently most patients are offered treatment with a standard chemotherapy drug depending on their cancer type.
- Conditions
- Pancreatic Adenocarcinoma Metastatic, Ovarian Serous Adenocarcinoma, Colorectal Cancer Metastatic
- Trial name
- CAM-PLEX (NCT02179970)
- Testing
- Plerixafor
- Where
- United Kingdom
- Volunteers
- 26 people
- Sponsor
- CCTU- Cancer Theme
Nasopharyngeal Carcinoma (NPC)
Molecular Research on Predictive Efficacy and New Therapeutic Targets for Nasopharyngeal Carcinoma
To analyze the spatiotemporal dynamic evolution of nasopharyngeal carcinoma before and after immunotherapy and during tumor progression, 2~3 key cell subsets or node molecules were screened to predict the curative effect.
- Trial name
- NCT07198802
- Testing
- No Intervention
- Volunteers
- 600 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Locally Advanced Rectal Cancer, Distant Metastasis
Constructing a Multimodal Imaging System to Predict the Risk of Heterochronous Metastasis of Rectal Cancer
The goal of this observational study is to construct a multimodal intelligent model to predict the risk of heterochronous metastasis of rectal cancer, which is helpful for individualized diagnosis and treatment and follow-up…
- Trial name
- MIS-MRC (NCT06293612)
- Testing
- No intervention was administrated to the two cohorts.
- Where
- China
- Volunteers
- 302 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Oesophageal Adenocarcinoma, T Cells
Will a Pre-therapy Exercise Intervention Improve the Outcomes of Patients With Advanced Oesophageal Cancer?
Background Regular exercise can significantly improve physical and mental health during cancer treatment and reduce the time needed in the hospital.
- Conditions
- Oesophageal Adenocarcinoma, T Cells, Tumor Microenvironment, Exercise
- Trial name
- OPTIMUS (NCT07375420)
- Testing
- Low intensity exercise, High intensity exercise
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- University of Surrey
Classical Hodgkin Lymphoma
Microenvironmental Trial of Classical Hodgkin Lymphoma in Adolescents
Background. Classical Hodgkin's lymphoma (cHL) in adolescents between 15 and 18 years shows a higher disease-related mortality and the overall prognosis is worse than both children and adults. Objectives.
- Trial name
- LH2004ME (NCT06814860)
- Where
- Italy
- Volunteers
- 36 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna